Sign in
Taking people in United StatesPhase 1

IDE034 for Advanced Solid Tumors Including Lung, Colorectal, Ovarian and Prostate Cancers

Tests IDE034 in adults with advanced solid tumors that carry B7-H3 and PTK7.

Key facts

Who runs it
IDEAYA Biosciences
Where
Austin, Celebration, Denver, Detroit, Duarte, East Brunswick, Fairfax, Fort Worth, Houston, Irvine, Irving, Lake Success, Nashville, New Haven, New York, Plantation, San Antonio, Sarasota, Spokane, and West Valley City, United StatesSee the 22 sitesAlso in 2 other countries, 5 sites
Registry title
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Status
Recruiting
Phase
Phase 1
People taking part
150 people, planned
Started
24 Feb 2026
Expected to end
30 Jul 2027
Type of study
Interventional, 2 groups
Treatments tested
  • IDE034
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic solid tumors that carry the markers B7-H3 and PTK7, whose cancer has grown or returned after at least one earlier treatment.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced, recurrent or metastatic solid tumors: NSCLC, ESCC, endometrial cancer, HGSOC, HNSCC, TNBC, CRC or CRPC. The disease must be measurable on scans. ECOG performance status must be 0 or 1.
Earlier treatment
The cancer must have grown or returned after at least one line of therapy, or the person cannot tolerate other effective standard treatments. Prior B7-H3 or PTK7 antibody-drug conjugate treatment is not allowed.
Biomarker or test result
The tumor must express B7-H3 and PTK7. An archival tissue sample is needed for testing. For TNBC, the tumor must be negative for estrogen receptor, progesterone receptor and HER2.

Main reasons for not taking part

  • Symptomatic brain or leptomeningeal metastases
  • Another cancer within 2 years before the first dose
  • Positive HIV test, known or suspected viral hepatitis, or active uncontrolled infection
  • History of interstitial pneumonitis or other serious lung disease
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Participant must be at least 18 years of age or the age of maturity per local regulations
  • Participants with advanced recurrent or metastatic solid tumors expressing B7-H3 and PTK7 in the following indications: NSCLC, ESCC, endometrial cancer, HGSOC, HNSCC, TNBC (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [HER2] negative), CRC, and CRPC who have radiologically progressed or recurred on at least one line of therapy or is intolerant to additional effective standard therapies
  • Archival tissue sample for testing
  • Measurable disease
  • Have Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
  • Have adequate bone marrow and organ function
  • Able to comply with contraceptive/barrier requirements

Who cannot take part

  • Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose
  • Have clinically significant cardiac abnormalities and/or cerebrovascular disease (stroke) within 6 months before the first dose
  • Have history of interstitial pneumonitis, current noninfectious pneumonitis requiring steroid therapy; known or suspected interstitial pneumonitis as seen on screening imaging; other moderate to severe lung diseases seriously affecting respiratory function within 3 months before the first dose
  • Have history of severe infections within 4 weeks prior to the start of study treatment, including but not limited to bacteremia, severe pneumonia, or other serious infectious complications requiring hospitalization
  • If participants had adverse reactions to previous antitumor treatment that have not recovered to guidelines of CTCAE Grade ≤ 1 and Grade 2 peripheral neurological symptoms
  • Have received chemotherapy within 3 weeks of first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 3 weeks before the first dose of IMP or other investigational products within 4 weeks of first dose of IMP
  • Administration of any of the following; Current use or anticipated need for food or drugs that are known strong CYP3A4/5 inhibitors or inducers; Have prior treatment with B7-H3 or PTK7 antibody-drug conjugate (ADC); Have prior treatment with a topoisomerase I inhibitor (TOP1i), including an ADC with a TOP1i payload, within 6 months of first dose of IMP; Have received radiotherapy within 2 weeks prior to study entry; Have undergone major surgery or trauma within 4 weeks prior to study entry; Have received live attenuated vaccine within 28 days prior to the first dose or are expected to receive live attenuated vaccine during the study treatment; Female participants who are pregnant, lactating, or planning to become pregnant during the study period to 7 months after the last dose of IMP; Are known to be allergic to any component or excipient of the IMP product or have a history of severe allergic reactions to other monoclonal antibody/fusion protein drugs; Participants with complications in the eye including ulcers in the eye, and severe dry eye
  • Active uncontrolled infection
  • Have history of immunodeficiency, with a positive human immunodeficiency virus (HIV) test at screening
  • Participants with known or suspected viral hepatitis
  • Have history of active tuberculosis within 1 year before enrollment
  • Known symptomatic brain metastases or leptomeningeal metastasis
  • Have uncontrolled tumor-associated pain

Where in United States

Also in 2 other countries, 5 sites

  • NEXT Texas LLC - AustinAustin, United StatesContact: Sheena SahotaTaking people
  • AdventHealth CelebrationCelebration, United StatesContact: Guru SonpavdeTaking people
  • Sarah Cannon Research Institute at HealthONEDenver, United StatesContact: Gerald FalchookTaking people
  • Karmanos Cancer InstituteDetroit, United StatesContact: Wasif SaifTaking people
  • City of Hope Comprehensive Cancer CenterDuarte, United StatesContact: Eric HolmquistTaking people
  • START - New JerseyEast Brunswick, United StatesContact: Bruno FangTaking people
  • NEXT Texas LLC - VirginiaFairfax, United StatesContact: Alexander SpiraTaking people
  • START Dallas Fort Worth, LLCFort Worth, United StatesContact: Henry XiongTaking people
  • MD AndersonHouston, United StatesContact: Timothy YapTaking people
  • NEXT Texas LLC - HoustonHouston, United StatesContact: Jennifer SegarTaking people
  • City of Hope Orange County Lennar Foundation Cancer CenterIrvine, United StatesContact: Lee HongTaking people
  • NEXT Texas LLC - DallasIrving, United StatesContact: Michael SongTaking people
  • START New York Long Island, LLCLake Success, United StatesContact: Geraldine O'Sullivan CoyneTaking people
  • SCRI Oncology PartnersNashville, United StatesContact: Deepak BhamidipatiTaking people
  • Yale Cancer CenterNew Haven, United StatesContact: Patricia LoRussoTaking people
  • Columbia University Irving Medical CenterNew York, United StatesContact: Brian Hendrick (principal investigator)Taking people
  • Florida Clinical Trials Group.Plantation, United StatesContact: Harshad AminTaking people
  • NEXT Texas LLC - San AntonioSan Antonio, United StatesContact: David SommerhalderTaking people
  • Start San Antonio, LLCSan Antonio, United StatesContact: Kyriakos PapadopoulosTaking people
  • Florida Cancer SpecialistsSarasota, United StatesContact: Manish PatelTaking people
  • Medical Oncology AssociatesSpokane, United StatesContact: Arvind ChaudhryTaking people
  • START Mountain Region, LLCWest Valley City, United StatesContact: Jose PachecoTaking people

About the trial

What the trial wants to find out

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

The 2 groups in the trial

  • Part 1:IDE034 Dose EscalationTreatment being tested

    IDE034 Dose Escalation Successive cohorts of participants will be treated with increasing doses of IDE034 until the maximum tolerated dose or the recommended dose for expansion is determined

    Treatment: IDE034

  • Part 2: IDE034 Dose ExpansionTreatment being tested

    IDE034 Dose Expansion To further assess the safety, tolerability, and preliminary antitumor activity at one or more dose levels of IDE034 selected from dose escalation

    Treatment: IDE034

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
Plain-language title
IDE034 for Advanced Solid Tumors Including Lung, Colorectal, Ovarian and Prostate CancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 November 2026